Roman Tsubin / Shutterstock.com
The proliferation of brands, combined with the financial and PR consequences of a potential rebrand in the event of infringement, has made selecting a trademark trickier than ever. Christina Martini and Virginia Wolk Marino of DLA Piper report.
In the challenging and complex world of life sciences product development, choosing a brand name that survives numerous trademark office and regulatory clearance processes is essential.
An effective pharmaceutical or medical product name can become a significant source of value to companies in this industry, and can serve to both differentiate a product and engender loyalty in a competitive market.
Given the high stakes, pharma companies often retain specialists to help compile lists of names for global legal consideration and brand clearance, a process that usually entails several rounds of searching and often includes both preliminary and more in-depth analyses. Preliminary trademark searches provide a review of nearly identical trademark applications and registrations.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Christina Martini,Virginia Wolk Marino, DLA Piper, trademark, brands, USANs, FDA, INNs, life sciences,